Ovagen vs Dermorphin
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
OvagenRecovery & Repair
Dermorphin- Summary
- Ovagen is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, primarily targeting liver tissue. It supports hepatocyte function, liver cell regeneration, and protection against hepatic aging and disease. Ovagen is used in protocols for chronic liver disease, hepatoprotection, and metabolic liver conditions including fatty liver disease.
- Dermorphin is a naturally occurring heptapeptide opioid isolated from the skin of South American phyllomedusine frogs. It is one of the most potent endogenous mu-opioid receptor agonists known, approximately 30-40 times more potent than morphine by weight. Explored for pain management and fatigue modulation.
- Half-Life
- Short (minutes); sustained gene-regulatory effects
- Estimated 30-60 minutes (longer than endorphins due to D-Ala)
- Admin Route
- SubQ, Oral
- Subcutaneous (research), Intrathecal (research), Intranasal (research)
- Research
- —
- —
- Typical Dose
- 10 mg per day
- Not established for human use; research doses vary widely
- Frequency
- Daily for 10–30 days
- Not established
- Key Benefits
- Hepatoprotective effects against toxic, viral, and metabolic liver damage
- Promotes hepatocyte regeneration and liver tissue repair
- May reduce liver fibrosis progression
- Supports liver metabolic function and detoxification capacity
- Anti-aging effects on hepatic tissue
- Useful in NAFLD/MASH supportive protocols
- Compatible with NAD+, glutathione, and BPC-157 in liver health stacks
- Potent analgesia superior to morphine on a per-weight basis
- May reduce perception of fatigue in high-intensity activity
- Longer-lasting than endogenous opioids due to D-amino acid substitution
- Research tool for mu-opioid receptor pharmacology
- Potential therapeutic application in refractory pain
- Side Effects
- Generally well tolerated
- Mild injection site reactions
- No clinically significant hepatotoxicity reported
- High addiction and dependence potential (mu-opioid agonism)
- Respiratory depression at high doses
- Nausea, vomiting, constipation
- Sedation and cognitive impairment
- +2 more
- Stacks With
- —
- —